Cypress Capital Management (Wyoming)’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$318	–	189
2023 Q4	$318	Hold	100	–	–	﹤0.01%	161
2023 Q3	$330	Hold	100	–	–	﹤0.01%	167
2023 Q2	$330	Hold	100	–	–	﹤0.01%	162
2023 Q1	$331	Buy	+100	New	+$350	﹤0.01%	155

Other funds holding LUMO

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

GWM

Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s LUMO Position: Q1 2024 in Review

Cypress Capital Management (Wyoming) sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2024, closing a stake of 100 shares — an estimated $318 sold.

Cypress Capital Management (Wyoming) first reported a position in LUMO in Q1 2023 and held it in 4 quarters. The position peaked at $331 in Q1 2023. 36 funds tracked by Wall St. Rank hold LUMO as of Q1 2024.

Cypress Capital Management (Wyoming) reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 100 Lumos Pharma, Inc. Common Stock shares in Q1 2024, an estimated $318.
Cypress Capital Management (Wyoming) first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
Cypress Capital Management (Wyoming)'s Lumos Pharma, Inc. Common Stock position peaked at $331 in Q1 2023.
36 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2024.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q1 2024, filed 9 May 2024.